{"symbol":"SH600276","secucode":"600276.SH","items":[{"title":"药明康德回应被美列入“中国军工企业”名单；恒瑞医药三款新药获批临床丨医药早参","summary":"丨2026年6月10日星期三丨NO.1药明康德回应被美列入“中国军工企业”名单：将立即采取措施挑战及纠正这一错误认定6月9日，药明康德在港交所公告：公司注意到，2026年6月8日（美国时间），美国国防部错误地将药明康德列入其根据1260H条款认定的“中国军工企业”正式更新版名单中。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606103765989018.html","info_code":"NW202606103765989018","show_time_timestamp":1781054366000,"show_time":"2026-06-10 09:19:26","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606103765989018.html","url":"http://finance.eastmoney.com/news/1354,202606103765989018.html","code":"202606103765989018","infoCode":"NW202606103765989018","recordId":null,"source":null,"title":"药明康德回应被美列入“中国军工企业”名单；恒瑞医药三款新药获批临床丨医药早参","updateTime":0,"showDateTime":1781054366000,"publishDate":0,"sRatingName":null,"summary":"丨2026年6月10日星期三丨NO.1药明康德回应被美列入“中国军工企业”名单：将立即采取措施挑战及纠正这一错误认定6月9日，药明康德在港交所公告：公司注意到，2026年6月8日（美国时间），美国国防部错误地将药明康德列入其根据1260H条款认定的“中国军工企业”正式更新版名单中。"}},{"title":"恒瑞医药：三款新药获临床试验批准 将开展乳腺癌联合用药Ⅰb/Ⅱ期研究","summary":"中证智能财讯恒瑞医药（600276）6月10日公告，公司及子公司山东盛迪医药有限公司、广东恒瑞医药有限公司近日收到国家药监局核准签发关于HRS-6209胶囊、HRS-8080片、HRS-9813胶囊的《药物临床试验批准通知书》，将于近期开展临床试验。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606103765988537.html","info_code":"NW202606103765988537","show_time_timestamp":1781054008000,"show_time":"2026-06-10 09:13:28","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606103765988537.html","url":"http://finance.eastmoney.com/news/1354,202606103765988537.html","code":"202606103765988537","infoCode":"NW202606103765988537","recordId":null,"source":null,"title":"恒瑞医药：三款新药获临床试验批准 将开展乳腺癌联合用药Ⅰb/Ⅱ期研究","updateTime":0,"showDateTime":1781054008000,"publishDate":0,"sRatingName":null,"summary":"中证智能财讯恒瑞医药（600276）6月10日公告，公司及子公司山东盛迪医药有限公司、广东恒瑞医药有限公司近日收到国家药监局核准签发关于HRS-6209胶囊、HRS-8080片、HRS-9813胶囊的《药物临床试验批准通知书》，将于近期开展临床试验。"}},{"title":"期待中国创新药跑出“加速度”","summary":"处在转型升级关键节点的中国创新药，持续获得全球药企青睐，近一个月里，多笔合作潜在交易总金额超百亿美元。创新药物研发国家科技重大专项纵深推进、药品审评审批改革持续增效，创新药出海热度不断高涨，中国创新药产业站上新起点。新一轮技术浪潮下，全球药物研发迎来一场颠覆性变革，创新范式和效率路径正被重新定义。","source":null,"url":"http://finance.eastmoney.com/news/1348,202606103765541897.html","info_code":"NW202606103765541897","show_time_timestamp":1781038252000,"show_time":"2026-06-10 04:50:52","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606103765541897.html","url":"http://finance.eastmoney.com/news/1348,202606103765541897.html","code":"202606103765541897","infoCode":"NW202606103765541897","recordId":null,"source":null,"title":"期待中国创新药跑出“加速度”","updateTime":0,"showDateTime":1781038252000,"publishDate":0,"sRatingName":null,"summary":"处在转型升级关键节点的中国创新药，持续获得全球药企青睐，近一个月里，多笔合作潜在交易总金额超百亿美元。创新药物研发国家科技重大专项纵深推进、药品审评审批改革持续增效，创新药出海热度不断高涨，中国创新药产业站上新起点。新一轮技术浪潮下，全球药物研发迎来一场颠覆性变革，创新范式和效率路径正被重新定义。"}},{"title":"恒瑞医药：公司近期进行了股份回购，详见于交易所网站上披露的相关公告","summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司近期进行了股份回购，详见于交易所网站上披露的相关公告。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606093765393677.html","info_code":"NW202606093765393677","show_time_timestamp":1781010600000,"show_time":"2026-06-09 21:10:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606093765393677.html","url":"http://finance.eastmoney.com/news/1354,202606093765393677.html","code":"202606093765393677","infoCode":"NW202606093765393677","recordId":null,"source":null,"title":"恒瑞医药：公司近期进行了股份回购，详见于交易所网站上披露的相关公告","updateTime":0,"showDateTime":1781010600000,"publishDate":0,"sRatingName":null,"summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司近期进行了股份回购，详见于交易所网站上披露的相关公告。"}},{"title":"恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%","summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司始终高度重视全体股东利益，致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。（1）公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。","source":null,"url":"http://finance.eastmoney.com/news/1354,202606093765312960.html","info_code":"NW202606093765312960","show_time_timestamp":1781006040000,"show_time":"2026-06-09 19:54:00","publish_time_timestamp":0,"publish_time":"","update_time_timestamp":0,"update_time":"","raw":{"uniqueUrl":"http://finance.eastmoney.com/a/202606093765312960.html","url":"http://finance.eastmoney.com/news/1354,202606093765312960.html","code":"202606093765312960","infoCode":"NW202606093765312960","recordId":null,"source":null,"title":"恒瑞医药：2025年公司实现营业收入316.29亿元，同比增长13.02%","updateTime":0,"showDateTime":1781006040000,"publishDate":0,"sRatingName":null,"summary":"证券日报网讯6月9日，恒瑞医药在互动平台回答投资者提问时表示，公司始终高度重视全体股东利益，致力于发展好主营业务，以扎实的经营基本面维护公司长期价值，从而以更好的发展回馈股东。（1）公司经营业绩稳步提升，整体发展态势持续向好。2025年全年，公司实现营业收入316.29亿元，同比增长13.02%；归属于上市公司股东的净利润77.11亿元，同比增长21.69%。"}}]}